Investments

– Index –
Investments | Disinvestments

Date: 15/11/2017
Category: Investments

XELTIS CLOSES A €45 MILLION ROUND AND YSIOS ATTEND, A STRATEGIC INVESTOR, CURRENT INSTITUTIONAL AND BUSINESS ANGELS.

Ysios Capital, Spanish venture capital firm, leader in investments on the life sciences sector, has announced its closure, with oversubscription, of the Series C financing round – for a total amount of 45 million euros – from the Swiss company Xeltis. Ysios Capital has participated in the round led by a strategic investor and with the participation of a large number of private investors, joining them to the company’s board of directors. The existing institutional investors (LSP, Kurma and VI) have also participated in the round.

This round will allow the company to advance in the clinical activities development, as well as, in product development and on the market of its innovative product programs, which are based on innovative biomaterials applicable to heart valves and specifically to aortic valves and pulmonary valves. This is one of the largest investment rounds for a private company of cardiovascular medical devices in 2017.

“Xeltis is proud to be able to treat patients with the need to replace their heart valves through their natural tissue regeneration technology. This approach allows a substantial improvement in the patient’s quality life, while reducing costs to the healthcare system”, says Laurent Grandidier, CEO of Xeltis.

The Xeltis heart valves allow the patient’s own body to naturally regenerate the heart valve tissue through a very innovative therapeutic approach based on the line of a Nobel Prize in Chemistry research Jean-Marie Lehn, supramolecular chemistry, in the biomaterials field. This technology triggers a natural biological action that, once implanted, the biomaterial in a device form (like an aortic valve) causes its impregnation with the patient’s own tissue. Once covered and repopulated with natural tissue, the biomaterial ends up disappearing, being absorbed by the patient without side effects, thus generating a new, natural and fully functional valve.

“The Xeltis investment reinforces the constant commitment of Ysios Capital for disruptive innovation in technologies applied to health, Xeltis has developed a new generation of products in the cardiology field, that only a few years ago was science fiction and today are a reality in clinical phase, with important advances for the patients quality life and resounding savings for healthcare systems”, says Josep Ll. Sanfeliu, Partner and Operations responsible in Ysios Capital.

“For this investment we have counted on the opinion of international experts among which stand out opinion leaders, such as Dr. José Luis Pomar (Hospital Clinic) and Dr. Georgia Sarquella Brugada (Hospital de Sant Joan de Deu)”.

In industrialized countries, it is estimated that heart valve disease affects around 2% of the population, with hundreds of thousands of patients performing interventions with heart valves each year and whose number increases with the population aging. In general, patients must bear the risk of valve replacement procedures and the use of long-term medications with potentially serious side effects.

About Ysios Capital 

Ysios Capital is a management business of venture capital companies, specialized on investments in life sciences companies’ field of and in particular, in biomedicine, diagnostics and medical technologies. Founded in 2008, Ysios Capital has 200 million euros under management distributed in two funds. Its second fund, Ysios BioFund II Innvierte, has a size of 126,4 million euros and already has 12 investee companies.

About Xeltis 

Xeltis is a medical device company in clinical stage that develops the first heart valves and blood vessels that allow the natural heart valve restoration function by the body itself through a therapeutic approach called Endogenous Tissue Restoration (ETR). The company’s cardiovascular implants are made of bioabsorbable polymers based on science awarded by the Nobel Prize. Xeltis has closed a series B financing of $33 million ($30 million in 2014, with an extension of $3 million in 2015).

Download (PDF 140Kb)
Share in social networks:

– Index –
Previous | Investments | Disinvestments | Next